Scanned by

    Norton

    Norton™ Safe Web

    Elucidating the role of modifying brain iron levels in managing RLS

    Elucidating the role of modifying brain iron levels in managing RLS

    03:26 |
    Download Here

    You Might Also Like:

    Parkinson's disease modification through c-Abl inhibition

    Parkinson's disease modification through c-Abl inhibition

    4:55 |
    BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis

    BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis

    3:51 |
    The use of precision medicine in Parkinson’s disease

    The use of precision medicine in Parkinson’s disease

    3:00 |
    The impact of hypertension on neurovascular function in neurodegenerative diseases

    The impact of hypertension on neurovascular function in neurodegenerative diseases

    5:46 |
    Biomarkers for the diagnosis of Parkinson’s disease

    Biomarkers for the diagnosis of Parkinson’s disease

    4:12 |
    Overlap between functional neurological disorders and PD

    Overlap between functional neurological disorders and PD

    3:48 |
    Dopaminergic agents diminish the response to subsequent non-dopaminergic treatment in RLS

    Dopaminergic agents diminish the response to subsequent non-dopaminergic treatment in RLS

    1:49 |
    Advancing chronobiology and circadian health in clinical practice

    Advancing chronobiology and circadian health in clinical practice

    2:01 |
    The development of circadian medicine: focusing on the chronobiology of disorders

    The development of circadian medicine: focusing on the chronobiology of disorders

    1:18 |
    Elucidating the role of modifying brain iron levels in managing RLS

    Elucidating the role of modifying brain iron levels in managing RLS

    3:26 |
    The future of drug-resistant epilepsy management

    The future of drug-resistant epilepsy management

    2:08 |
    Update on disease-modifying therapies in Parkinson’s disease

    Update on disease-modifying therapies in Parkinson’s disease

    4:47 |
    Differentiating obstructive and central sleep apnea via polysomnography

    Differentiating obstructive and central sleep apnea via polysomnography

    1:07 |
    How is amyloid beta cleared from the brain and why does this system fail?

    How is amyloid beta cleared from the brain and why does this system fail?

    5:21 |
    Establishing the North American Prodromal Synucleinopathy (NAPS) consortium

    Establishing the North American Prodromal Synucleinopathy (NAPS) consortium

    2:12 |
    Revisiting the concept of autoimmune epilepsy

    Revisiting the concept of autoimmune epilepsy

    2:02 |
    Understanding epilepsy-related neurodegeneration

    Understanding epilepsy-related neurodegeneration

    2:13 |
    The mechanism of action of CNM-Au8 and its potential in various neurodegenerative diseases

    The mechanism of action of CNM-Au8 and its potential in various neurodegenerative diseases

    1:25 |
    Abnormalities in color vision in patients with multiple sclerosis

    Abnormalities in color vision in patients with multiple sclerosis

    1:24 |
    Pathophysiology and clinical manifestations of autoimmune encephalitis

    Pathophysiology and clinical manifestations of autoimmune encephalitis

    1:53 |